CAPTRUST Financial Advisors
SPRO icon

CAPTRUST Financial Advisors’s Spero Therapeutics SPRO Stock Holding History

CAPTRUST Financial Advisors’s Portfolio SPRO Stock Details SPRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-473
Closed – – 3779
2022
Q2 		$0 Sell
473
-43
-8% -$125 ﹤0.01% 5126
2022
Q1 		$4K Hold
516
– – ﹤0.01% 4274
2021
Q4 		$8K Hold
516
– – ﹤0.01% 3858
2021
Q3 		$9K Hold
516
– – ﹤0.01% 3685
2021
Q2 		$7K Buy
516
+223
+76% +$3.12K ﹤0.01% 3718
2021
Q1 		$4K Buy
+293
New +$5.16K ﹤0.01% 3820

Other funds holding SPRO

ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
AVAI
Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
M
Murchinson Toronto, Ontario, Canada $791M AUM 68.08% 1-Year Est. Return

CAPTRUST Financial Advisors's SPRO Position: Q3 2022 in Review

CAPTRUST Financial Advisors sold out of Spero Therapeutics (SPRO) in Q3 2022, closing a stake of 473 shares.

CAPTRUST Financial Advisors first reported a position in SPRO in Q1 2021 and held it in 6 quarters. The position peaked at $9K in Q3 2021. 69 funds tracked by Wall St. Rank hold SPRO as of Q3 2022.

  • CAPTRUST Financial Advisors reported no remaining Spero Therapeutics position as of Q3 2022 after selling out during the quarter.
  • CAPTRUST Financial Advisors sold 473 Spero Therapeutics shares in Q3 2022.
  • CAPTRUST Financial Advisors first reported a position in Spero Therapeutics in Q1 2021 and held it in 6 quarters.
  • CAPTRUST Financial Advisors's Spero Therapeutics position peaked at $9K in Q3 2021.
  • 69 funds tracked by Wall St. Rank held Spero Therapeutics as of Q3 2022.

Based on CAPTRUST Financial Advisors's 13F filing for Q3 2022, filed 16 Nov 2022.